Supercharge Your Innovation With Domain-Expert AI Agents!

Novel antibody specific for CLEC14A and uses thereof

一种抗体、特异性的技术,应用在抗体、抗体模拟物/支架、非有效成分的医用配制品等方向,能够解决分子机制未被清楚地鉴定等问题

Active Publication Date: 2015-09-09
YULI TECH CO LTD
View PDF12 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Despite increased interest in clec14a in recent years, its molecular mechanism has not been clearly identified

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel antibody specific for CLEC14A and uses thereof
  • Novel antibody specific for CLEC14A and uses thereof
  • Novel antibody specific for CLEC14A and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0171] Example 1: Cell culture and transfection

[0172] Human umbilical vein endothelial cells (HUVEC, Lonza, Baltimore, MD, USA) were maintained in Endothelial Growth Medium-2 (EGM-2). Mouse aortic endothelial cells (MAEC) and COS-7 cells were cultured in Dulbecco's modified Eagle's medium containing 10% (v / v) fetal bovine serum and 1% (v / v) penicillin / streptomycin. Maintain cells at 37 °C and 5% CO 2 Humid CO 2 - In a controlled incubator (Sanyo, Panasonic Healthcare Company, Secaucus, NJ, USA). at 37°C and 8% CO 2 , HEK293F cells were maintained in Freestyle with 1% (v / v) penicillin / streptomycin in a humidified shaking incubator shaker (Infors HT, Bottmingen, Switzerland). TM 293 expression medium (Invitrogen). HUVEC and COS-7 cells were transfected with vectors encoding GFP, clec14a-GFP (wild-type clec14a) or clec14aΔCTLD-GFP (clec14a CTLD deletion mutant) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions .

Embodiment 2

[0173] Embodiment 2: Construct and prepare the CTLD Fc fusion protein of human and mouse

[0174] DNA encoding amino acid residues 31-172 of hCTLD was amplified using primers 5'-TCGCGCGGCCGCTGCTCGGCCTCGGGGGCCTGC-3' (SEQ ID NO: 1) and 5'-TCGCCTCGAGCTTGCACAGGTAGCCGTTGG-3' (SEQ ID NO: 2). DNA encoding the same residues of mCTLD was amplified using primers 5'-TCGCGGCCCAGGCGGCCTGTTCGGCCTCGGGGGCTTG-3' (SEQ ID NO: 3) and 5'-TCGCGGCCGGCCTGGCCCTTGCATAGGTAGCCATCGG-3' (SEQ ID NO: 4). The PCR fragment (NEB, Ipswich, MA, USA) was digested with Sfi I (NEB, Ipswich, MA, USA) and cloned into the modified mammalian expression vector pCEP4 (Invitrogen), wherein pCEP4 was located at 3 of the cloning site. ' region encoding the hinge and CH2-CH3 domains of human IgG1 (a gift from Dr. Chung, Seoul National University, Seoul, South Korea). The ligation product was transformed into competent Escherichia coli DH5α cells, and plasmid DNA was prepared. 0.75 mg of various DNAs were transfected into HE...

Embodiment 3

[0175] Example 3: Pre-cleaning of synthetic human scFv libraries

[0176] The synthetic human scFv library was reamplified (Barbas CF. Phage display: a laboratory manual. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press; 2001). For pre-washing of Fc binders, human immunoglobulin-G (Green Cross Pharma Derivatives Corp, Yong-in, Korea) was immobilized on protein A Sepharose, and antibody-protein A complexes were incubated with the library at 37°C for 2 hours . After brief centrifugation, collect the supernatant and discard the pellet. Repeat this process twice. The final supernatant was analyzed by phage ELISA to assess the extent of washing.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided is an antibody specifically binding to the CTLD (C-type lectin like domain) of clecl4a (C-type lectin domain family 14, member A), a method for preparing the antibody, a composition for suppressing angiogenesis comprising the antibody, a method for suppressing angiogenesis by administering the antibody or the composition, a composition for preventing or treating cancer comprising the antibody, a method for treating cancer by administering the antibody or the composition, a composition for diagnosing cancer comprising the antibody, a kit for diagnosing cancer comprising the composition, a method for diagnosing cancer using the composition, a composition for suppressing angiogenesis comprising a material for inhibiting expression of clecl4a, a kit for angiogenesis comprising the composition, a method for suppressing angiogenesis or treating cancer using the composition, and the use of the CTLD of clecl4a as an epitope for an antibody suppressive of angiogenesis.

Description

technical field [0001] The present invention relates to novel antibodies that specifically bind member A of the C-type lectin domain family 14 (clec14a) and uses thereof. More specifically, the present invention relates to an antibody specifically binding to the C-type lectin-like domain (CTLD) of clecl4a, a method for producing the antibody, a composition comprising the antibody for inhibiting angiogenesis, by administering the antibody or the composition A method for inhibiting angiogenesis, a composition comprising an antibody for preventing or treating cancer, a method for treating cancer by administering the antibody or the composition, a composition comprising an antibody for diagnosing cancer, a composition comprising the same for diagnosing cancer A kit for the composition, a method for diagnosing cancer using the composition, a composition for inhibiting angiogenesis comprising a substance for inhibiting the expression of clec14a, a kit for angiogenesis comprising the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C12N15/13A61K39/395A61P35/00
CPCC07K16/18C07K7/08C07K14/435C07K2317/21G01N33/53C07K2319/30A61K47/48538C07K14/7056C07K16/2851C07K2317/622C07K2317/565C07K2317/34A61K47/6843A61P1/04A61P13/12A61P17/02A61P17/06A61P27/06A61P29/00A61P35/00A61P35/02A61P35/04A61P9/00G01N2333/7056
Inventor 李硕默奇珉庚郑美贤崔钟湁
Owner YULI TECH CO LTD
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More